

Special Issue

Omics Approaches to Study Extracellular Vesicles for Diagnosis and Treatment of Cancer 2.0

Message from the Guest Editor

Within the last decade, extracellular vesicles (EVs) have been recognized as a new mechanism of intercellular communication through the delivery of bioactive molecules such as proteins, metabolites, lipids, and nucleic acids, including messenger RNAs (mRNAs) and microRNAs (miRNAs). Their essential role in cancer biology has been highlighted in several recent studies. Cancer cell-derived EVs promote tumor progression by modulating the immune response, reprogramming the tumor microenvironment, and stimulating metastasis. Profiling the contents of EVs may further elucidate their role in cancer progression, early detection, and identification of therapeutic targets. New advancements in omics-based techniques such as genomics, transcriptomics, proteomics, and metabolomics, have contributed to a deeper understanding of molecular mechanisms through which EVs influence cancer biology. Therefore, the purpose of this Special Issue is to publish omics-based approaches studying extracellular vesicles to advance diagnosis and treatment of cancer on a molecular level.

Guest Editor

Dr. Zoran Minic

Department of Chemistry and Biomolecular Sciences, John L. Holmes Mass Spectrometry Facility, Faculty of Science, University of Ottawa, Ottawa, ON K1N6N5, Canada

Deadline for manuscript submissions

closed (31 March 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/121700

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).